LIPJ Inhibitors
LIPJ inhibitors belong to a distinctive chemical class known for their specific interactions with the LIPJ enzyme. This class of inhibitors is characterized by a unique structural framework that enables them to selectively target and modulate the activity of LIPJ. LIPJ, short for Lipase J, is an enzyme that plays a crucial role in lipid metabolism within biological systems. As a lipase, LIPJ is involved in catalyzing the hydrolysis of ester bonds in lipids, facilitating the breakdown of triglycerides into fatty acids and glycerol. This enzymatic activity is vital for cellular processes related to energy storage and utilization.
The chemical structure of LIPJ inhibitors is meticulously designed to interact with specific binding sites on the LIPJ enzyme, disrupting its normal catalytic function. Researchers have focused on elucidating the intricate molecular mechanisms through which these inhibitors bind to LIPJ, aiming to understand their inhibitory effects at a detailed level. By deciphering the structural nuances of the LIPJ inhibitor interaction, scientists can gain insights into potential applications and implications for lipid metabolism regulation. The study of LIPJ inhibitors contributes to the broader understanding of enzymatic processes involved in lipid metabolism, paving the way for advancements in various fields such as biochemistry and molecular biology.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically binds to FKBP12 and the resulting complex inhibits mTOR (mammalian target of rapamycin), which is a downstream regulator of protein synthesis and cell growth. Inhibition of mTOR can reduce protein synthesis, including potentially those of LIPJ, if it is involved in mTOR regulated pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K (phosphoinositide 3-kinases). PI3K signaling is upstream of mTOR and can regulate protein synthesis. By inhibiting PI3K, LY294002 can indirectly lead to decreased activity of mTOR and subsequently lower the synthesis of proteins including LIPJ if it is regulated by this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which in turn inhibits ERK activation in the MAPK/ERK pathway. This pathway is involved in the regulation of gene expression and cell proliferation. Inhibition of this pathway can lead to decreased expression of various proteins, potentially including LIPJ if it is regulated through this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting the p38 MAPK signaling pathway, SB203580 can affect transcription factors and gene expression, potentially reducing the expression of proteins like LIPJ if they are downstream in this signaling cascade. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. Similar to LY294002, by inhibiting PI3K, wortmannin can decrease the activity of mTOR and thereby reduce protein synthesis, indirectly affecting the synthesis of LIPJ if it is part of the PI3K/AKT/mTOR pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, leading to the inhibition of the MAPK/ERK signaling pathway. It can consequently decrease the expression of various proteins, potentially including LIPJ if it is regulated by the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinases), which are part of the MAPK pathway. By inhibiting JNK, SP600125 can alter transcriptional activity and reduce the expression of certain proteins, including possibly LIPJ if its expression is dependent on JNK signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that blocks the degradation of proteins, leading to increased protein levels in the cell. This can cause a feedback inhibition on the synthesis of new proteins, possibly including LIPJ if it is subject to regulation by proteostasis mechanisms. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic organisms by interfering with the translocation step in protein synthesis, thus inhibiting translation. This can lead to a decrease in the overall pool of proteins, including LIPJ if it is being actively translated. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can change the chromatin structure and affect gene expression. By altering transcription, it might decrease the expression of specific proteins, including LIPJ if it is regulated by histone acetylation. | ||||||